144 related articles for article (PubMed ID: 19049913)
1. Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis.
Sebba AI; Emkey RD; Kohles JD; Sambrook PN
Bone; 2009 Mar; 44(3):423-7. PubMed ID: 19049913
[TBL] [Abstract][Full Text] [Related]
2. Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate.
Miller PD; Delmas PD; Huss H; Patel KM; Schimmer RC; Adami S; Recker RR
Calcif Tissue Int; 2010 Oct; 87(4):305-13. PubMed ID: 20737140
[TBL] [Abstract][Full Text] [Related]
3. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies.
Harris ST; Blumentals WA; Miller PD
Curr Med Res Opin; 2008 Jan; 24(1):237-45. PubMed ID: 18047776
[TBL] [Abstract][Full Text] [Related]
4. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
[TBL] [Abstract][Full Text] [Related]
5. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.
Epstein S; Jeglitsch M; McCloskey E
Curr Med Res Opin; 2009 Dec; 25(12):2951-60. PubMed ID: 19835464
[TBL] [Abstract][Full Text] [Related]
6. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
[TBL] [Abstract][Full Text] [Related]
7. Beyond daily dosing: clinical experience.
Cooper C
Bone; 2006 Apr; 38(4 Suppl 1):S13-7. PubMed ID: 16520105
[TBL] [Abstract][Full Text] [Related]
8. Predictors of Ibandronate Efficacy for the Management of Osteoporosis: A Meta-Regression Analysis.
Ma Z; Li Y; Zhou M; Huang K; Hu H; Liu X; Xu X
PLoS One; 2016; 11(3):e0150203. PubMed ID: 26930292
[TBL] [Abstract][Full Text] [Related]
9. Risk reduction of non-vertebral fractures with intravenous ibandronate: post-hoc analysis from DIVA.
Sambrook P; Cranney A; Adachi JD
Curr Med Res Opin; 2010 Mar; 26(3):599-604. PubMed ID: 20055751
[TBL] [Abstract][Full Text] [Related]
10. Regional distribution of spine and hip QCT BMD responses after one year of once-monthly ibandronate in postmenopausal osteoporosis.
Engelke K; Fuerst T; Dasic G; Davies RY; Genant HK
Bone; 2010 Jun; 46(6):1626-32. PubMed ID: 20226286
[TBL] [Abstract][Full Text] [Related]
11. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment.
Sebba AI
Clin Ther; 2008 Mar; 30(3):443-52. PubMed ID: 18405784
[TBL] [Abstract][Full Text] [Related]
12. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
Liberman UA; Weiss SR; Bröll J; Minne HW; Quan H; Bell NH; Rodriguez-Portales J; Downs RW; Dequeker J; Favus M
N Engl J Med; 1995 Nov; 333(22):1437-43. PubMed ID: 7477143
[TBL] [Abstract][Full Text] [Related]
13. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis.
Recker R; Stakkestad JA; Chesnut CH; Christiansen C; Skag A; Hoiseth A; Ettinger M; Mahoney P; Schimmer RC; Delmas PD
Bone; 2004 May; 34(5):890-9. PubMed ID: 15121021
[TBL] [Abstract][Full Text] [Related]
14. Increased bone mineral density with monthly intravenous ibandronate contributes to fracture risk reduction in patients with primary osteoporosis: three-year analysis of the MOVER study.
Hagino H; Yoshida S; Hashimoto J; Matsunaga M; Tobinai M; Nakamura T
Calcif Tissue Int; 2014 Dec; 95(6):557-63. PubMed ID: 25377907
[TBL] [Abstract][Full Text] [Related]
15. Cortical bone loss at the tibia in postmenopausal women with osteoporosis is associated with incident non-vertebral fractures: results of a randomized controlled ancillary study of HORIZON.
Popp AW; Buffat H; Cavelti A; Windolf M; Perrelet R; Senn C; Lippuner K
Maturitas; 2014 Mar; 77(3):287-93. PubMed ID: 24485216
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
[TBL] [Abstract][Full Text] [Related]
17. Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study.
Harris ST; Reginster JY; Harley C; Blumentals WA; Poston SA; Barr CE; Silverman SL
Bone; 2009 May; 44(5):758-65. PubMed ID: 19168160
[TBL] [Abstract][Full Text] [Related]
18. [Ibandronate (Bonviva) in the treatment of postmenopausal osteoporosis].
Reginster JY
Rev Med Liege; 2006 Nov; 61(11):783-6. PubMed ID: 17191748
[TBL] [Abstract][Full Text] [Related]
19. [Once-weekly teriparatide treatment on osteoporosis].
Nakano T
Clin Calcium; 2014 Jan; 24(1):100-5. PubMed ID: 24369286
[TBL] [Abstract][Full Text] [Related]
20. Monthly oral ibandronate 100 mg is as effective as monthly intravenous ibandronate 1 mg in patients with various pathologies in the MOVEST study.
Hagino H; Ito M; Hashimoto J; Yamamoto M; Endo K; Katsumata K; Asao Y; Matsumoto R; Nakano T; Mizunuma H; Nakamura T
J Bone Miner Metab; 2018 May; 36(3):336-343. PubMed ID: 28389932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
